Caffeine metabolites are inhibitors of the nuclear enzyme poly(ADP-ribose)polymerase-1 at physiological concentrations

Biochemical Pharmacology

Volumn 72, Issue 7, 2006, Pages 902-910

  Geraets, Liesbeth ^a   Moonen, Harald J J ^a   Wouters, Emiel F M ^b   Bast, Aalt ^a   Hageman, Geja J ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Inhibition; Methylxanthines; NAD+; Necrosis; Oxidative stress; Poly(ADP ribose)polymerase 1

Indexed keywords

1 METHYLURIC ACID; 1 METHYLXANTHINE; 1,7 DIMETHYLURIC ACID; 3 METHYLXANTHINE; 7 METHYLXANTHINE; 8 METHYLXANTHINE; AMINOPHYLLINE; CAFFEINE; CAFFEINE DERIVATIVE; DRUG METABOLITE; HYDROGEN PEROXIDE; HYPOXANTHINE; INOSINE; METHYLXANTHINE DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PARAXANTHINE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); POLYMER; THEOBROMINE; THEOPHYLLINE; UNCLASSIFIED DRUG; XANTHINE;

ANTIOXIDANT ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; ELECTRON SPIN RESONANCE; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PURIFICATION; HUMAN; HUMAN CELL; LUNG ALVEOLUS EPITHELIUM; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIC N-OXIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRON SPIN RESONANCE SPECTROSCOPY; ENDOTHELIAL CELLS; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYDROGEN PEROXIDE; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; NAD; NUCLEAR PROTEINS; OXIDATIVE STRESS; POLY(ADP-RIBOSE) POLYMERASES; SPIN TRAPPING; STRUCTURE-ACTIVITY RELATIONSHIP; THEOPHYLLINE; XANTHINES;

EID: 33748068455     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.06.023     Document Type: Article

References (41)

1. Dantzer F., de La Rubia G., Menissier-De Murcia J., Hostomsky Z., de Murcia G., and Schreiber V. Base excision repair is impaired in mammalian cells lacking poly(ADP-ribose) polymerase-1. Biochemistry 39 25 (2000) 7559-7569
2. Masson M., Niedergang C., Schreiber V., Muller S., Menissier-de Murcia J., and de Murcia G. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol 18 6 (1998) 3563-3571
3. Hassa P.O., and Hottiger M.O. The functional role of poly(ADP-ribose)polymerase 1 as novel coactivator of NF-kappaB in inflammatory disorders. Cell Mol Life Sci 59 9 (2002) 1534-1553
4. Hassa P.O., Buerki C., Lombardi C., Imhof R., and Hottiger M.O. Transcriptional coactivation of nuclear factor-kappaB-dependent gene expression by p300 is regulated by poly(ADP)-ribose polymerase-1. J Biol Chem 278 46 (2003) 45145-45153
5. Szabo C., Lim L.H., Cuzzocrea S., Getting S.J., Zingarelli B., Flower R.J., et al. Inhibition of poly (ADP-ribose) synthetase attenuates neutrophil recruitment and exerts antiinflammatory effects. J Exp Med 186 7 (1997) 1041-1049
6. Ha H.C., Hester L.D., and Snyder S.H. Poly(ADP-ribose) polymerase-1 dependence of stress-induced transcription factors and associated gene expression in glia. Proc Natl Acad Sci USA 99 5 (2002) 3270-3275
7. Veres B., Radnai B., Gallyas Jr. F., Varbiro G., Berente Z., Osz E., et al. Regulation of kinase cascades and transcription factors by a poly(ADP-ribose) polymerase-1 inhibitor, 4-hydroxyquinazoline, in lipopolysaccharide-induced inflammation in mice. J Pharmacol Exp Ther 310 1 (2004) 247-255
8. Kiefmann R., Heckel K., Doerger M., Schenkat S., Kupatt C., Stoeckelhuber M., et al. Role of PARP on iNOS pathway during endotoxin-induced acute lung injury. Intens Care Med 30 7 (2004) 1421-1431
9. Zingarelli B., Hake P.W., O'Connor M., Denenberg A., Wong H.R., Kong S., et al. Differential regulation of activator protein-1 and heat shock factor-1 in myocardial ischemia and reperfusion injury: role of poly(ADP-ribose) polymerase-1. Am J Physiol Heart Circ Physiol 286 4 (2004) H1408-H1415
10. Liaudet L., Pacher P., Mabley J.G., Virag L., Soriano F.G., Hasko G., et al. Activation of poly(ADP-Ribose) polymerase-1 is a central mechanism of lipopolysaccharide-induced acute lung inflammation. Am J Respir Crit Care Med 165 3 (2002) 372-377
11. Garcia Soriano F., Virag L., Jagtap P., Szabo E., Mabley J.G., Liaudet L., et al. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med 7 1 (2001) 108-113
12. Hageman G.J., Larik I., Pennings H.J., Haenen G.R., Wouters E.F., and Bast A. Systemic poly(ADP-ribose) polymerase-1 activation, chronic inflammation, and oxidative stress in COPD patients. Free Radic Biol Med 35 2 (2003) 140-148
13. Goto S., Xue R., Sugo N., Sawada M., Blizzard K.K., Poitras M.F., et al. Poly(ADP-ribose) polymerase impairs early and long-term experimental stroke recovery. Stroke 33 4 (2002) 1101-1106
14. Schraufstatter I.U., Hinshaw D.B., Hyslop P.A., Spragg R.G., and Cochrane C.G. Oxidant injury of cells. DNA strand-breaks activate polyadenosine diphosphate-ribose polymerase and lead to depletion of nicotinamide adenine dinucleotide. J Clin Invest 77 4 (1986) 1312-1320
15. Ha H.C., and Snyder S.H. Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc Natl Acad Sci USA 96 24 (1999) 13978-13982
16. Suto M.J., Turner W.R., Arundel-Suto C.M., Werbel L.M., and Sebolt-Leopold J.S. Dihydroisoquinolinones: the design and synthesis of a new series of potent inhibitors of poly(ADP-ribose) polymerase. Anticancer Drug Des 6 2 (1991) 107-117
17. Banasik M., Komura H., Shimoyama M., and Ueda K. Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J Biol Chem 267 3 (1992) 1569-1575
18. Rankin P.W., Jacobson E.L., Benjamin R.C., Moss J., and Jacobson M.K. Quantitative studies of inhibitors of ADP-ribosylation in vitro and in vivo. J Biol Chem 264 8 (1989) 4312-4317
19. Sharma S., Stutzman J.D., Kelloff G.J., and Steele V.E. Screening of potential chemopreventive agents using biochemical markers of carcinogenesis. Cancer Res 54 22 (1994) 5848-5855
20. Soriano F.G., Pacher P., Mabley J., Liaudet L., and Szabo C. Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase. Circ Res 89 8 (2001) 684-691
21. + depletion via PARP-1 inhibition in human pulmonary epithelial cells. Biochem Biophys Res Commun 338 (2005) 1805-1810
22. Tang-Liu D.D., Williams R.L., and Riegelman S. Disposition of caffeine and its metabolites in man. J Pharmacol Exp Ther 224 1 (1983) 180-185
23. Kalow W., and Tang B.K. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 53 5 (1993) 503-514
24. Decker P., Miranda E.A., de Murcia G., and Muller S. An improved nonisotopic test to screen a large series of new inhibitor molecules of poly(ADP-ribose) polymerase activity for therapeutic applications. Clin Cancer Res 5 5 (1999) 1169-1172
25. Brown J.A., and Marala R.B. Development of a high-throughput screening-amenable assay for human poly(ADP-ribose) polymerase inhibitors. J Pharmacol Toxicol Meth 47 3 (2002) 137-141
26. Aposhian H.V., and Kornberg A. Enzymatic synthesis of deoxyribonucleic acid. IX. The polymerase formed after T2 bacteriophage infection of Escherichia coli: a new enzyme. J Biol Chem 237 (1962) 519-525
27. Zatman L.J., Kaplan N.O., Colowick S.P., and Ciotti M.M. Effect of isonicotinic acid hydrazide on diphosphopyridine nucleotidases. J Biol Chem 209 2 (1954) 453-466
28. Jacobson E.L., and Jacobson M.K. Tissue NAD as a biochemical measure of niacin status in humans. Meth Enzymol 280 (1997) 221-230
29. Bradbury D.A., Simmons T.D., Slater K.J., and Crouch S.P. Measurement of the ADP:ATP ratio in human leukaemic cell lines can be used as an indicator of cell viability, necrosis and apoptosis. J Immunol Meth 240 1/2 (2000) 79-92
30. Claycomb W.C. Poly(adenosine diphosphate ribose) polymerase activity and nicotinamide adenine dinucleotide in differentiating cardiac muscle. Biochem J 154 2 (1976) 387-393
31. Kroger H., Ehrlich W., Klewer M., Gratz R., Dietrich A., and Miesel R. The influence of antagonists of poly(ADP-ribose) metabolism on acetaminophen hepatotoxicity. Gen Pharmacol 27 1 (1996) 167-170
32. Thiemermann C., Bowes J., Myint F.P., and Vane J.R. Inhibition of the activity of poly(ADP ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal muscle. Proc Natl Acad Sci USA 94 2 (1997) 679-683
33. Zingarelli B., Salzman A.L., and Szabo C. Genetic disruption of poly (ADP-ribose) synthetase inhibits the expression of P-selectin and intercellular adhesion molecule-1 in myocardial ischemia/reperfusion injury. Circ Res 83 1 (1998) 85-94
34. Trucco C., Oliver F.J., de Murcia G., and Menissier-de Murcia J. DNA repair defect in poly(ADP-ribose) polymerase-deficient cell lines. Nucl Acids Res 26 11 (1998) 2644-2649
35. Schultz N., Lopez E., Saleh-Gohari N., and Helleday T. Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. Nucl Acids Res 31 17 (2003) 4959-4964
36. Burkart V., Wang Z.Q., Radons J., Heller B., Herceg Z., Stingl L., et al. Mice lacking the poly(ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin. Nat Med 5 3 (1999) 314-319
37. van Dam R.M., and Feskens E.J. Coffee consumption and risk of type 2 diabetes mellitus. Lancet 360 9344 (2002) 1477-1478
38. Salazar-Martinez E., Willett W.C., Ascherio A., Manson J.E., Leitzmann M.F., Stampfer M.J., et al. Coffee consumption and risk for type 2 diabetes mellitus. Ann Intern Med 140 1 (2004) 1-8
39. The Diabetes Control, Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 14 (1993) 977-986
40. Pickup J.C. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diab Care 27 3 (2004) 813-823
41. Boulares A.H., Zoltoski A.J., Sherif Z.A., Jolly P., Massaro D., and Smulson M.E. Gene knockout or pharmacological inhibition of poly(ADP-ribose) polymerase-1 prevents lung inflammation in a murine model of asthma. Am J Respir Cell Mol Biol 28 3 (2003) 322-329